Literature DB >> 1503448

In vitro antistaphylococcal activity and testing of RP 59500, a new streptogramin, by two methods.

K E Aldridge1, D D Schiro, L M Varner.   

Abstract

The in vitro antistaphylococcal activity of RP 59500, a new streptogramin, was comparable to those of vancomycin and teicoplanin against Staphylococcus aureus, and RP 59500 was the most active agent against coagulase-negative staphylococci. All staphylococcal strains were inhibited by 4 micrograms of RP 59500 per ml, including multiply resistant strains. Broth microdilution and agar dilution testing gave comparable results in 97% of the tests with RP 59500.

Entities:  

Mesh：

Substances：

Year:  1992        PMID： 1503448      PMCID： PMC189457          DOI： 10.1128/AAC.36.4.854

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  1 in total

1.  In vitro activity of RP 59500, a semisynthetic injectable pristinamycin, against staphylococci, streptococci, and enterococci.

Authors:  R J Fass
Journal:  Antimicrob Agents Chemother       Date:  1991-03       Impact factor: 5.191
  1 in total
  14 in total

Review 1.  Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.

Authors:  H M Lamb; D P Figgitt; D Faulds
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

Review 2.  Current perspectives on glycopeptide resistance.

Authors:  N Woodford; A P Johnson; D Morrison; D C Speller
Journal:  Clin Microbiol Rev       Date:  1995-10       Impact factor: 26.132

Review 3.  Emerging resistance to antimicrobial agents in gram-positive bacteria. Enterococci, staphylococci and nonpneumococcal streptococci.

Authors:  M G Cormican; R N Jones
Journal:  Drugs       Date:  1996       Impact factor: 9.546

4.  Influence of resistance to streptogramin A type antibiotics on the activity of quinupristin-dalfopristin in vitro and in experimental endocarditis due to Staphylococcus aureus.

Authors:  V Zarrouk; B Bozdogan; R Leclercq; L Garry; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2000-05       Impact factor: 5.191

Review 5.  Quinupristin-dalfopristin.

Authors:  H M Bryson; C M Spencer
Journal:  Drugs       Date:  1996-09       Impact factor: 9.546

Review 6.  Antimicrobial susceptibility of coagulase-negative staphylococci.

Authors:  G L Archer; M W Climo
Journal:  Antimicrob Agents Chemother       Date:  1994-10       Impact factor: 5.191

7.  Activities of the combination of quinupristin-dalfopristin with rifampin in vitro and in experimental endocarditis due to Staphylococcus aureus strains with various phenotypes of resistance to macrolide-lincosamide-streptogramin antibiotics.

Authors:  V Zarrouk; B Bozdogan; R Leclercq; L Garry; C Feger; C Carbon; B Fantin
Journal:  Antimicrob Agents Chemother       Date:  2001-04       Impact factor: 5.191

8.  In vivo activities and penetration of the two components of the streptogramin RP 59500 in cardiac vegetations of experimental endocarditis.

Authors:  B Fantin; R Leclercq; M Ottaviani; J M Vallois; B Maziere; J Duval; J J Pocidalo; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1994-03       Impact factor: 5.191

9.  In vitro activity of RP59500, an injectable streptogramin antibiotic, against vancomycin-resistant gram-positive organisms.

Authors:  L A Collins; G J Malanoski; G M Eliopoulos; C B Wennersten; M J Ferraro; R C Moellering
Journal:  Antimicrob Agents Chemother       Date:  1993-03       Impact factor: 5.191

10.  Critical influence of resistance to streptogramin B-type antibiotics on activity of RP 59500 (quinupristin-dalfopristin) in experimental endocarditis due to Staphylococcus aureus.

Authors:  B Fantin; R Leclercq; Y Merlé; L Saint-Julien; C Veyrat; J Duval; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1995-02       Impact factor: 5.191
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.